DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
The motivating force behind My GI Health met initial resistance. After all, it came from a company executive who professed that his goal was to benefit all companies within that therapeutic area.
Tom McCourt says he's "a marketing guy who hopefully understands a little about drug development" even as he guided drugs like Prilosec to market.
There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.
The Facebook for doctors launches Pages, allowing healthcare companies to establish a presence on Sermo and engage with physicians.
Time is everything, yet no one has enough of it. But especially in healthcare marketing, time and timing win customers.
Discover why even digitally native physicians can no longer abide the flood of information e-sent their way.
The doc shortage may be due, in part, to changing marriage patterns; Olympus settles anti-kickback case; U.K. says Imbruvica is too expensive
Perfectionists in the world of pharma marketing can no longer rely on the status quo, given current threats to traditional commercial models and the rise of digital HCP engagement.
Finn Partners surveyed 1,000 adults to understand how often young Americans change doctors and how they talk to pharmacists.
Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.
Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug
The contract sales organization plans to sell its commercial services business to Publicis Healthcare Communications Group.
Many patients allow doctors to access their social-media accounts; Turing will reportedly lower the price of Daraprim by 10%; WebMD reports boost in traffic
Patient portals are an underutilized resource for a population hungry for health information.
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
The deal combines two of Merck's wholly owned subsidiaries.
Amarin begins legally promoting off-label uses of its prescription fish-oil drug, while Pacira sues the FDA over the label for its pain drug, Exparel.
Ashley Madison's lesson must be heeded. For all the good pharma has done for the world, it has also created its share of ethical quagmires.
The deal is expected to complement the company's digital health platform.
The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.
Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.
With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.
Despite increasing income, many doctors are turning away from self-employment.
Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.
Though it's unlikely that patient portals will ever be accessed as often as mobile banking, ensuring that the patient portal provides obvious value to a patient's experience with a healthcare provider remains an important point.
Traditional tactics of connecting with physicians are quickly becoming obsolete.
A recent Medscape survey found that under-40s were more likely to work for a healthcare organization than were their older colleagues, trading autonomy for work-life balance and income predictability.
The third lifestyle survey shows that doctors are battling the bulge just like everyone else.
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Following positive outcomes data, a new diabetes class is on the rise
- Creative partners should push pharma clients to tell better stories